Continental has announced the launch of the Grand Prix 5000 S TR .
The new Grand Prix 5000 S TR is 20% faster and 50g lighter than the Grand Prix 5000 TL thanks to its 2-ply structure, with 28% more sidewall protection, said the brand. Available in black or black and transparent sidewall colourways, the Grand Prix 5000 S TR utilises Continental’s BlackChili Compound for the ‘ultimate balance of rolling resistance, grip and longevity’, Vectran Breaker for puncture protection and tear resistance, and Lazer Grip for ‘outstanding’ cornering.
Rather than simply update the Grand Prix 5000 TL, Continental said it has ‘reinvented’ its approach to tubeless-ready road tyres. The Grand Prix 5000 S TR is hookless compatible and tubeless-ready as standard, thanks to a new user-optimised tubeless system and robust construction.
Oliver Anhuth, head of marketing TwoWheel Tyres, Continental, said: “Following on from the success of the Grand Prix 5000 – which has arguably become one of the most well-loved performance road tyres in the world – we are delighted to announce the launch of Grand Prix 5000 S TR.
“We created this new tyre to combine maximum performance with ease of use and reliability, regardless of whether a cyclist chooses to race, to spend long days out exploring the roads, to ride through summer or all year round. All new hookless compatibility and tubeless capabilities will put convenience without compromise at the heart of every cyclist’s ride.”
The Grand Prix 5000 S TR has been tested in training, racing, and performance laboratories by multiple teams across the professional peloton in 2021. This season it has been ridden by Grand Tour stage winners and world champions alike, including Filippo Ganna’s (INEOS-Grenadiers) World Championship time trial victory in September as well as Sonny Colbrelli’s win (Bahrain-Victorious) at Paris-Roubaix.
This latest performance tyre comes to market as Continental celebrates its 150th anniversary. The tyre has been under development since 2019, with more than 18 months of product testing and trials completed.